AMA: FDA action on OTC naloxone will save people from overdoses

| 1 Min Read

Statement attributable to:
Patrice A. Harris, MD, MA
President-elect, chair of the AMA Opioid Task Force
American Medical Association

“The AMA applauds the FDA and Commissioner Gottlieb for today’s action to provide labeling that would allow for over-the-counter availability of naloxone, a move that will save people from opioid-related overdose. Naloxone has saved tens of thousands of lives, and the AMA continues to strongly urge physicians to co-prescribe naloxone to patients at risk of opioid-related overdose.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Counselor listens to a patient

Advancing mental health and SUD parity—from promise to practice

| 5 Min Read
Smiling patient looks up at doctor

New initiatives shape the next phase of well-being work

| 7 Min Read
Shopper in the bread aisle of a grocery store

The bottom line for your patients on new U.S. dietary guidelines

| 5 Min Read
Jose Colon, MD, featured on "Health vs. Hype" AMA podcast

9 things patients should know about sleep trends

| 6 Min Read